TRDA vs WVE
TRDA: Entrada Therapeutics is developing a new class of intracellular genetic medicines using its proprietary endosomal escape vehicle technology to treat serious neuromuscular and retinal diseases. WVE: Wave Life Sciences is a clinical-stage biotech company developing stereopure nucleic acid therapeutics via its proprietary PRISM platform to treat genetically defined diseases.
Side-by-side fundamentals
| Metric | TRDA | WVE | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $5.53 | $3.47 | |
| Market cap | $215M | $684M | |
| Net margin FY2025, SEC XBRL | -565.5% | -478.3% | WVE higher |
| Operating margin FY2025, SEC XBRL | -621.1% | -504.1% | WVE higher |
| ROE FY2025, SEC XBRL | -47.0% | -39.4% | WVE higher |
| ROA FY2025, SEC XBRL | -38.1% | -32.0% | WVE higher |
| Debt / equity as of 2026-09-02 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-09-02 | -94.1% | -30.4% | WVE higher |
| Revenue CAGR (3y) SEC XBRL | -55.6% | +127.1% | WVE higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 1.18 | 1.47 | |
| 1-year return as of 2026-10-08 close | -10.2% | -52.8% | TRDA higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.